MIRA
INFORM REPORT
|
Report Date : |
19.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
CELOGEN PHARMA PRIVATE LIMITED |
|
|
|
|
Registered Office : |
A – 502, Tirupati
Arcade, Plot No. 7, Sector – 21, Kharghar, Navi Mumbai – 410210 |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
13.04.2005 |
|
|
|
|
Com. Reg. No.: |
11-152619 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24230MH2005PTC152619 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
MUMG11818C |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AABCL1038M |
|
|
|
|
Legal Form : |
Private Limited
Liability Company |
|
|
|
|
Line of Business : |
Manufacturer of
Pharmaceutical Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Maximum Credit Limit : |
- |
|
|
|
|
Status : |
New Company |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject has no
track of performance and finance. It can be
considered for any business dealings on safe and secured trade terms and
conditions, initially |
LOCATIONS
|
Registered Office : |
A – 502, Tirupati
Arcade, Plot No. 7, Sector – 21, Kharghar, Navi Mumbai – 410210 |
|
Website : |
|
|
|
|
|
Factory 1 : |
Shree Nand Dham, 411-
B, Sector – 11, CBD Belapur, Navi Mumbai – 400614 |
|
Tel. No.: |
91-22-56743201 |
|
Fax No.: |
91-22-56743202 |
DIRECTORS
|
Name : |
Mr. Rabi Narayan
Nayak |
|
Designation : |
Director |
|
Address : |
Plot No. 404, Manorama
Housing Society, Plot No. 63, Sector – 11, Kharghar, Navi Mumbai – 410210 |
|
Date of Appointment : |
13.04.2005 |
|
|
|
|
Name : |
Mr. Sanjay
Velappan Nair |
|
Designation : |
Director |
|
Address : |
A – 502, Tirupati
Arcade, Plot No. 7, Sector – 21, Kharghar, Navi Mumbai – 410210 |
|
Date of Appointment : |
13.04.2005 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of
Pharmaceutical Products. |
|
|
|
|
Products : |
v
Analgesics,
Anti-inflammatory, Agents & Antipyretics (NSAIDS) v
Non-Opiods
Analgesics & NSAIDS v
Anti
Allergics & Drugs used in Anaphylaxis v
Anesthetics v
Local
Anesthetics v
Pre-Operative
Medication v
Anti
Ulcerants v
H2
Receptor Antagonists v
Anti
Convulsants, Anti Epileptics v
Proton
Pump Inhibitors v
Other
Generics v
Gastro
Intestinal Drugs v
Anti
Spasmodic Drugs v
Laxatives v
Anti-Asthmatic v
Adrenal
Hormones & Other Synthetics Substitutes v
Intestinal
Anthelmintics v
Other
Antibiotics / Anti Infectives v
Anti
Tuberculosis Drugs v
Anti
Malarial Drugs v
Betalactams v
Anti
Fungal Drugs v
Anti
Protozoal Drugs v
Antihypertensive
Drugs v
Genito
Urinary Drugs v
Nutraceuticals v
Multi
Vitamins & Minerals v
Haematenic
Drugs v
Other
Specialities v
Vitamins v
Vitamin
E v
Multi
Vitamin + Mineral Branded v
HIV
Anti-Virals v
CNS
Agents v
Sedatives
& Anxiolytics v
Drugs
used in Psychotic Disorders v
High
Potency GLA Oils v
Anticoagulants
& Antithrombotics Agents v
Anti
Oxydants v
Cardiovascular
Agents v
Cholesterol
Reducers / Hypolipedemic Agents v
Anti-Cancer
Agents. |
GENERAL INFORMATION
|
Bankers : |
Bank
of Big Splash, Sector 17, Shop No. 126/66, |
|
|
|
|
Banking
Relations : |
Satisfactory |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
50000 |
Equity Shares |
Rs. 10.00 Each |
Rs. 0.500 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
10000 |
Equity Shares |
Rs. 10.00 Each |
Rs. 0.100 Millions |
FINANCIAL DATA
[all figures are in
Rupees Millions]
Nil
LOCAL AGENCY FURTHER INFORMATION
Business
To carry on in
India and aboard the business to manufacturer, produce, process, compound,
formulate, mix, concentrate, grade, freeze, distillate, boil, sterilize, buy,
sell, import, export, transport, store, dispose off, market, supply and to act
as exporter, agent, broker, adatias, representatives, consultant, collaborator,
stockiest, liasioner, middleman, job worker, in all types descriptions,
specification strengths and application of pharmaceutical and chemical product
of medicament in all its branches such as allopathic, Ayurvedic, herbal,
siddha, bio – chemic, injections, vitamin and products and all kinds medical
and surgical equipment
Form 8 Particular for
creation or modification of charges
|
Corporation identity number or foreign company registrations number of the company |
U24230MH2005PTC152619 |
|
Name of the company |
CELOGEN PHARMA PRIVATE LIMITED |
|
Address |
Shree Nand Dham, 411- B, Sector – 11, CBD Belapur, Navi Mumbai –
400614 |
|
This Form is for |
Creation of charge |
|
Type of Charges |
Equitable mortgage or mortgage of property by depositing the title deeds |
|
Particular of the charge holder |
Bank
of Big
Splash, Sector 17, Shop No. 126/66, |
|
Nature or description of the instrument creating charge |
Hypothecation agreement |
|
Date of the instrument creating charge |
08.02.2006 |
|
Amount Secure by the charge |
Rs. 3.400 millions |
|
Brief of the principal terms and conditions and extent and operation of the charge |
Interest for Packing Credit – 3.50% below BPLR i.e. 7.00% p.a. Interest for Term Loan – 2.75% over BPLR i.e. 13.25% p.a. Term Loa Repayable – 36 monthly installments of Rs. 0.011 million + Interest Margin Money – 25% packing credit & 20% on Term Loan |
|
Description of the property charge whether it is a charge on |
Immovable properties, plant and machinery, stock in trade, book debts, vehicles and others If others, specify Consumable, stores & spares |
As per
Website Details
Guiding Principles at Celogen Pharma Private Limited
They believe that the essence of Pharma Production lies in the manufacture of Quality Products and Timely deliveries," which in turn creates customer value and satisfaction. Since its inception this has been the guiding principle enabling the Company to satisfy all their customers worldwide. The Company is constantly exploring possibilities to consolidate its presence and deliver value to clients.
All members at Celogen Pharma are individually and collectively committed to deliver the best in Pharmaceutical products and services in order to satisfy every customers needs through constant innovation, dedication, and providing a healthy work environment for all, and adopting the best in International practices.
It is noteworthy to mention that their facilities conform to WHO_GMP Standards and other regulatory specifications of different governing bodies.
Vision:
Grow to be a global pharma player, through excellence in core areas of
manufacturing & development.
To ensure better quality of life for people all over by providing medicines
& supplements of high standards, at affordable prices.
Philosophy:
The corporate philosophy at Celogen is serving customers with Qualitative,
Effective, and Well on Time deliveries of their products.
The stakeholders of the Company lay a great importance in the realization of the mentioned principles, thereby affecting a positive synergy to the entire Value Chain ultimately benefiting the customer
Company Policy
One of the core values of Celogen Pharma is that they conduct their business consistent with all applicable laws, and are honest in their dealings with customers, employees, partners, suppliers, and the community. Consistent with this value, Celogen is committed to establishing and maintaining an effective and comprehensive compliance programme in accordance with the relevant governmental bodies and their policies and it is the central component of its commitment to the highest standards of corporate conduct in all its dealings.
Subject’s Policy remains a living, breathing entity, constantly changing to meet the rising demands of the market and the business environment. Celogen continuously reviews and enhances its policies to bring to its business partners the fruits of continuous development, enhancement of productivity, with quality being the keyword.
These are all followed by a strict programme of adherence and compliance through:
1. Leadership and Structure
2. Written Standards
3. Education and Training
4. Internal Lines of Communication
5. Auditing and Monitoring
6. Responding to Potential violations/errors
7. Corrective Action Procedures
It is their commitment to be honest and
ethical in business dealings and corporate responsibility. The policies, procedures,
and programmatic elements outlined above represent a program responsive to
manufacturing and quality concerns, which is consistent with the values of the
Company.
Quality
Subject strives to conduct its business with
a total commitment to their Customers and their requirements. They define
quality as conformance to their Customer's needs, both internal and external;
and conformance to all quality requirements.
At Celogen, Quality is the prime motto. The systems and
procedures are well framed to monitor and control process at various stages, so
that the final product meets the required standards and specifications.
Their personnel involved are made aware of the Quality
requirements at each level.
Review and improvement of these systems and procedures at
various stages are done. SOPs are maintained and updated periodically and
systems are made in accordance with the Good Manufacturing Practice, to meet
international standards.
Manufacturing Location
Subject has entered into lease / license
agreements with three state of the art manufacturing sites for production of
its products. The manufacturing is done as per Formulations of Celogen that are
of top quality and conforming to stringent international standards.
It goes to show their commitment to quality that their own
personnel supervise their products being manufactured, to ensure online
control.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 40.70 |
|
|
1 |
Rs. 80.80 |
|
Euro |
1 |
Rs. 54.65 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
4 |
|
OPERATING SCALE |
1~10 |
- |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
- |
|
--PROFITABILIRY |
1~10 |
- |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
- |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
16 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|